CagriSema Protocol

Evidence Level: Emerging Evidence

Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.

Human evidence: Phase 3 randomized trial data (REDEFINE program) with published body-weight outcomes.

Animal evidence: Preceded by component-level rodent metabolic studies.

Introduction & Mechanism of Action

Combination cagrilintide/semaglutide studied for dual amylin and GLP-1 receptor signaling in weight research.

Fixed-ratio co-formulation pairing amylin-receptor agonism (satiety, gastric emptying) with GLP-1-receptor agonism (appetite, glycemic control) for additive weight effect.

Receptors/targets: Amylin receptor, GLP-1 receptor

Areas of Research Interest

• Dual amylin/GLP-1 signaling
• Weight-management research
• Metabolic marker studies

Benefits Reported in Research

• Dual-pathway appetite research
• Weight-management studies
• Metabolic marker research

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 1–2.4 mg

Reported frequency: 1× weekly, subcutaneous

Reported cycle duration: 12–24 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on CagriSema reports administration at 1–2.4 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Injection-site reaction
• Decreased appetite

Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy

Drug interactions

• Insulin/sulfonylureas — increased hypoglycemia risk
• Delayed gastric emptying may reduce absorption of concurrent oral medications

Safety

• Compounded gastrointestinal intolerance from two agonist mechanisms
• Thyroid C-cell risk associated with the GLP-1 component
• Gallbladder disease

Not yet a generally authorized medicine; combination-specific adverse-event profile still being characterized in ongoing trials.

Expected Results & Comparison

CagriSema and Retatrutide both target more than one receptor pathway; CagriSema pairs amylin with GLP-1, while Retatrutide pairs GIP, GLP-1 and glucagon. Trial-reported weight-loss magnitudes are broadly comparable between the two in separate (not head-to-head) trials.

References

Continue